(Q40389395)

20 September 2017

Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. (English)

1 reference

20 September 2017

1 reference

6

Kathryn M Edwards

1 reference

20 September 2017

Melissa Rosenberg

1

1 reference

20 September 2017

Robert Sparks

2

1 reference

20 September 2017

Ann McMahon

3

1 reference

20 September 2017

John Iskander

4

1 reference

20 September 2017

James D Campbell

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

28 May 2009

1 reference

20 September 2017

1 reference

20 September 2017

27

1 reference

20 September 2017

32

1 reference

20 September 2017

4278-4283

1 reference

The burden of influenza illness in children with asthma and other chronic medical conditions.

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

The underrecognized burden of influenza in young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Data mining in the US using the Vaccine Adverse Event Reporting System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Safety of the trivalent inactivated influenza vaccine among children: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

The safety of inactivated influenza vaccine in adults and children with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Methods of ensuring vaccine safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

The science of evaluation of adverse events associated with vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

A process for sentinel case review to assess causal relationships between smallpox vaccination and adverse outcomes, 2003-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Understanding vaccine safety information from the Vaccine Adverse Event Reporting System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

Response to Dr Halsey & AVEC: analyze both forests and trees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.023

10.1016/J.VACCINE.2009.05.023

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference